Last reviewed · How we verify
Keratoconjunctivitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Tobi · Novartis
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Keratoconjunctivitis patent landscape — cliff calendar, originator estates, attackable patents
- Keratoconjunctivitis treatment landscape brief
- Keratoconjunctivitis treatment updates RSS
Frequently asked questions about Keratoconjunctivitis
What drugs treat Keratoconjunctivitis?
Tracked treatments include Ramycin, Tobi, Vantobra, Nebcin.
What is the treatment for Keratoconjunctivitis?
Standard treatment for Keratoconjunctivitis includes Ramycin, Tobi, Vantobra, Nebcin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Keratoconjunctivitis patent cliff · Keratoconjunctivitis CI report
- Treatment: Ramycin
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Nebcin · University Hospital, Lille
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing